Home » Newsletters » BioWorld Science

BioWorld Science

April 21, 2008

View Archived Issues

Promising phase II results of idebenone in Duchenne muscular dystrophy

In vivo antitumor efficacy seen with Trop-2 antibody AR47A6.4.2

Preclinical studies test IMGN-901 against ovarian cancer, multiple myeloma

OPL-CCL2-LPM active in mouse model of MS

Novel analgesic agents disclosed in recent patent literature

FDA approves Alcon's Patanase nasal spray for seasonal allergic rhinitis

Santarus is to terminate U.S. copromotion agreement with Otsuka for Zegerid

MedImmune initiates phase I and phase II clinical trials of anti-IL-13 antibody CAT-354

DSMB recommends continuation of Anthera's phase II IMPACTS clinical trial of A-001

Paratek completes USD 40 million private placement to finance phase III studies of PTK-0796

Zelos and Aegis enter collaboration for intranasal delivery of ZT-031 for osteoporosis

Lev Pharmaceuticals submits complete response to FDA for Cinryze for hereditary angioedema

New PPAR agonists evaluated for lipid effects in mice

Modern Biosciences initiates phase I rimcazole trial in cancer

Recent patents report new treatment options for inflammatory and autoimmune diseases

Shionogi receives marketing and manufacturing approval for Irbetan

Boston Scientific acquires CryoCor for approximately USD 17.6

Insmed receives U.K. approval to initiate phase I study of follow-on biologic of Neupogen

Pfizer and Avant enter into licensing agreement for EGFRvIII vaccine CDX-110

Sepracor launches Omnaris nasal spray for allergic rhinitis in the U.S.

Arpida reports positive results from two pivotal phase III trials with iclaprim in cSSSI

GSK and Regulus enter strategic alliance to develop microRNA-targeted therapeutics

Orion seeks expanded indication for Stalevo in Parkinson's disease in U.S. and Europe

Renovo reports positive results from two phase II clinical trials of Juvista for scars

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...